OBJECTIVE: To investigate the acute efficacy and adverse side effects of methylphenidate (MPH) among survivors of childhood cancer [acute lymphoblastic leukemia (ALL) or brain tumor (BT)] with learning impairments. METHODS: Participants (N = 122) completed a two-day, in-clinic, double-blind, cross-over trial during which they received MPH (0.60 mg/kg of body weight) and placebo that were randomized in administration order across participants. Performance was evaluated using measures of attention, memory, and academic achievement. RESULTS: A significant MPH versus placebo effect was revealed on a measure of attention, cognitive flexibility, and processing speed (Stroop Word-Color Association Test). Male gender, older age at treatment, and higher intelligence were predictive of better medication response. No significant differences were found for number or severity of adverse side effects as a function of active medication. CONCLUSIONS:MPH shows some neurocognitive benefit and is well tolerated by the majority of children surviving ALL and BT.
RCT Entities:
OBJECTIVE: To investigate the acute efficacy and adverse side effects of methylphenidate (MPH) among survivors of childhood cancer [acute lymphoblastic leukemia (ALL) or brain tumor (BT)] with learning impairments. METHODS:Participants (N = 122) completed a two-day, in-clinic, double-blind, cross-over trial during which they received MPH (0.60 mg/kg of body weight) and placebo that were randomized in administration order across participants. Performance was evaluated using measures of attention, memory, and academic achievement. RESULTS: A significant MPH versus placebo effect was revealed on a measure of attention, cognitive flexibility, and processing speed (Stroop Word-Color Association Test). Male gender, older age at treatment, and higher intelligence were predictive of better medication response. No significant differences were found for number or severity of adverse side effects as a function of active medication. CONCLUSIONS: MPH shows some neurocognitive benefit and is well tolerated by the majority of children surviving ALL and BT.
Authors: Lisa S Kahalley; Vida L Tyc; Stephanie J Wilson; Jenna Nelms; Melissa M Hudson; Shengjie Wu; Xiaoping Xiong; Pamela S Hinds Journal: J Cancer Surviv Date: 2010-10-05 Impact factor: 4.442
Authors: Heather M Conklin; Susan Helton; Jason Ashford; Raymond K Mulhern; Wilburn E Reddick; Ronald Brown; Melanie Bonner; Bruce W Jasper; Shengjie Wu; Xiaoping Xiong; Raja B Khan Journal: J Pediatr Psychol Date: 2009-05-22
Authors: Heather M Conklin; Joanne Lawford; Bruce W Jasper; E Brannon Morris; Scott C Howard; Susan W Ogg; Shengjie Wu; Xiaoping Xiong; Raja B Khan Journal: Pediatrics Date: 2009-07 Impact factor: 7.124
Authors: Lauren E Cox; Jason M Ashford; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Robert J Ogg; Sima Jeha; Victoria W Willard; Lu Huang; Hui Zhang; Heather M Conklin Journal: Neurooncol Pract Date: 2015-03-13
Authors: Bruce W Jasper; Heather M Conklin; Joanne Lawford; E Brannon Morris; Scott C Howard; Shengjie Wu; Xiaoping Xiong; John Shelso; Raja B Khan Journal: Pediatr Blood Cancer Date: 2009-01 Impact factor: 3.167
Authors: Katherine H Moyer; Victoria W Willard; Alan M Gross; Kelli L Netson; Jason M Ashford; Lisa S Kahalley; Shengjie Wu; Xiaoping Xiong; Heather M Conklin Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Ping Zou; Yimei Li; Heather M Conklin; Raymond K Mulhern; Robert W Butler; Robert J Ogg Journal: Arch Clin Neuropsychol Date: 2012-10-18 Impact factor: 2.813